James F. Trotter, Brenda W. Gillespie, Norah A. Terrault, Michael M. Abecassis, Robert M. Merion, Robert S. Brown, Kim M. Olthoff, Paul H. Hayashi, Carl L. Berg, Robert A. Fisher, James E. Everhart, and the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study Group – 10 January 2011 – Information on the long‐term health of living liver donors is incomplete. Because changes in standard laboratory tests may reflect the underlying health of donors, results before and after donation were examined in the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study (A2ALL).

Sebastian Pratschke, Georgios Meimarakis, Stephan Mayr, Christian Graeb, Markus Rentsch, Reinhard Zachoval, Christiane Josephine Bruns, Axel Kleespies, Karl‐Walter Jauch, Florian Loehe, Martin Kurt Angele – 10 January 2011 – Proper liver perfusion is essential for sufficient organ function after liver transplantation. The aim of this study was to determine the effects of portal and arterial blood flow on liver function and organ survival after liver transplantation.

Vinay Sundaram, Deborah T. Jones, Nilesh H. Shah, Michael E. de Vera, Paulo Fontes, J. Wallis Marsh, Abhinav Humar, Jawad Ahmad – 10 January 2011 – Biliary complications remain a cause of morbidity after liver transplantation. The aim of this study was to determine whether changes in clinical practice in the era of the Model for End‐Stage Liver Disease (MELD) has affected biliary complications after liver transplantation. We retrospectively reviewed all deceased donor liver transplants at a single center.

Eishiro Mizukoshi, Yasunari Nakamoto, Kuniaki Arai, Tatsuya Yamashita, Akito Sakai, Yoshio Sakai, Takashi Kagaya, Taro Yamashita, Masao Honda, Shuichi Kaneko – 10 January 2011 – Many tumor‐associated antigens (TAAs) recognized by cytotoxic T cells (CTLs) have been identified during the last two decades and some of them have been used in clinical trials. However, there are very few in the field of immunotherapy for hepatocellular carcinoma (HCC) because there have not been comparative data regarding CTL responses to various TAAs.

Zong‐Gen Peng, Zhi‐Yun Zhao, Yan‐Ping Li, Yu‐Ping Wang, Lan‐Hu Hao, Bo Fan, Yu‐Huan Li, Yue‐Ming Wang, Yong‐Qiang Shan, Yan‐Xing Han, Yan‐Ping Zhu, Jian‐Rui Li, Xue‐Fu You, Zhuo‐Rong Li, Jian‐Dong Jiang – 10 January 2011 – Host cellular factor apolipoprotein B messenger RNA (mRNA)‐editing enzyme catalytic polypeptide‐like 3G (hA3G) is a cytidine deaminase that inhibits a group of viruses including human immunodeficiency virus‐1 (HIV‐1). In the continuation of our research on hA3G, we found that hA3G stabilizing compounds significantly inhibited hepatitis C virus (HCV) replication.

Trayana Kireva, Annette Erhardt, Gisa Tiegs, Herbert Tilg, Helmut Denk, Johannes Haybaeck, Elmar Aigner, Alexander Moschen, Jörg H. Distler, Georg Schett, Jochen Zwerina – 10 January 2011 – Chronic diseases of the biliary system are common and may cause fibrosis and eventually progression to liver cirrhosis. The aim was to define a new mouse model of a cholangiopathy leading to liver fibrosis in fra‐1tg mice. Liver pathology of fra‐1tg mice was analyzed in detail by histology and flow cytometry.

James Nelson, Kris Kowdley – 10 January 2011

Humphrey Hodgson, Clare Selden – 10 January 2011

William Sievert, Gregory J. Dore, Geoffrey W. McCaughan, Motoko Yoshihara, Darrell H. Crawford, Wendy Cheng, Martin Weltman, William Rawlinson, Bishoy Rizkalla, Jean K. DePamphilis, Stuart K. Roberts, on behalf of the CHARIOT Study Group – 10 January 2011 – Anemia may increase the likelihood of achieving a sustained virological response (SVR) during pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) infection. To determine whether hemoglobin decline is associated with SVR, we retrospectively evaluated the CHARIOT study of 871 treatment‐naïve HCV genotype 1 patients.

Jong Man Kim, Sung‐Joo Kim, Jae‐Won Joh, Choon Hyuck David Kwon, Sanghyun Song, Milljae Shin, Ju Ik Moon, Gaab Soo Kim, Seung Heui Hong, Suk‐Koo Lee – 10 January 2011 – Cytomegalovirus (CMV) infections contracted after liver transplantation put patients at an increased risk of morbidity and mortality. We analyzed the effects of CMV infection by time of onset, mortality, and graft failure risk factors in liver recipients who were CMV donor‐positive/recipient‐positive (D+/R+). We reviewed 618 medical records for consecutive adult liver transplant cases.